Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cytokinetics Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance from 2018 to 2022 is characterized by a consistent failure to generate economic value, as evidenced by negative economic profit in every reported period. A significant acceleration in value destruction is observed starting in 2021, indicating a widening gap between operating results and the required return on capital.

Net Operating Profit After Taxes (NOPAT)
A volatile and overall deteriorating trend is observed in operating profitability. Although a notable recovery occurred in 2020, with losses narrowing to -31.57 million, this improvement was short-lived. A severe decline followed, with losses expanding to -193.08 million in 2021 and reaching -460.02 million by the end of 2022, representing a substantial increase in operational deficits.
Cost of Capital
The cost of capital remained relatively stable throughout the analyzed period, fluctuating within a narrow corridor between a high of 15.33% in 2018 and a low of 13.97% in 2020. This stability suggests that the company's weighted average cost of capital did not undergo significant structural shifts, despite the volatility in its operating results.
Invested Capital
Invested capital exhibited atypical and highly volatile movements, remaining negative for the majority of the timeframe. A temporary shift to a positive value of 91.72 million occurred in 2021, followed by a return to a negative position of -117.41 million in 2022. Such fluctuations indicate significant instability in the capital base or unusual balance sheet dynamics.
Economic Profit
Economic profit remained consistently negative, confirming that the entity did not cover its cost of capital. The trajectory shows a brief peak in 2020 at -19.29 million before a sharp downward trend emerged. By December 31, 2022, economic profit declined to -443.12 million. The strong correlation between the decline in NOPAT and the decline in economic profit suggests that the erosion of value is primarily driven by escalating operating losses rather than changes in the cost of capital.

Net Operating Profit after Taxes (NOPAT)

Cytokinetics Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net loss.

4 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net loss.

7 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Loss Trend
The net loss demonstrates a consistent and significant increase over the five-year period. Beginning at approximately -106.3 million US dollars at the end of 2018, the net loss gradually worsened to -121.7 million in 2019 and further to -127.3 million in 2020. A sharper escalation is observed in 2021, with the net loss reaching approximately -215.3 million US dollars, followed by a substantial further decline to -389.0 million US dollars in 2022. This indicates increasing expenses, reduced revenues, or other factors contributing to growing financial challenges over time.
Net Operating Profit After Taxes (NOPAT) Trend
NOPAT follows a somewhat different trajectory from net loss but remains negative throughout the observed period. It starts at around -105.9 million US dollars in 2018 and deteriorates slightly to -119.5 million in 2019. In 2020, there is a notable improvement, with NOPAT improving substantially to approximately -31.6 million US dollars, indicating either a reduction in operating losses or improved operational efficiency during that year. However, this improvement is not sustained, as NOPAT declines sharply in 2021 to around -193.1 million, and further worsens to an estimated -460.0 million US dollars by the end of 2022. This sharp downturn in recent years suggests significant operational challenges impacting profitability after taxes.
Overall Financial Performance Insights
The increasing net losses alongside the fluctuating but largely negative NOPAT values suggest persistent financial difficulties with a notable deterioration in both net loss and operating profitability in the last two years of the data. The brief improvement in NOPAT in 2020 could reflect transient operational efficiencies or cost management, which were not maintained amid subsequent increases in losses. This pattern may warrant a deeper investigation into the underlying causes such as increased expenses, investments, or operational disruptions in the 2021 and 2022 periods.

Cash Operating Taxes

Cytokinetics Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The data presents a clear upward trend in cash operating taxes for the company over the observed period from December 31, 2018, to December 31, 2022. Starting at 102 thousand US dollars in 2018, the cash operating taxes increased significantly each year, peaking at 5,911 thousand US dollars by the end of 2021. However, in 2022, there was a noticeable decline to 4,236 thousand US dollars, indicating a reduction of approximately 28% from the previous year.

The absence of values for the income tax provision across all periods indicates either that such data was not reported or that there were no income tax provisions recognized during these years.

Overall, the cash operating taxes show a consistent upward trajectory with the exception of the last year, where a decline suggests possible changes in tax policy, operational conditions, or other factors impacting the tax liability related to cash operations. The lack of income tax provision data limits the ability to analyze comprehensive tax expense trends.


Invested Capital

Cytokinetics Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current portion of term loan
Short-term finance lease liabilities
Term loan, net, excluding current portion
Convertible notes, net
Long-term finance lease liabilities
Operating lease liability1
Total reported debt & leases
Stockholders’ equity (deficit)
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity (deficit)
Construction in progress6
Available-for-sale investments7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity (deficit).

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investments.


Total reported debt & leases
The total reported debt and leases show a consistent and significant upward trend over the five-year period. Beginning at $52.8 million in 2018, the figure rose sharply to $136.1 million in 2019 and remained relatively stable in 2020. From 2020 onwards, the debt level surged substantially, reaching $271.2 million in 2021 and further increasing to $751.3 million by the end of 2022. This dramatic rise in debt indicates a growing reliance on external financing or obligations over time.
Stockholders’ equity (deficit)
Stockholders’ equity exhibits considerable volatility throughout the period. Initially, it was positive at $25.9 million in 2018. However, it turned negative in 2019, reflecting a deficit of approximately $10.9 million. The position improved markedly in 2020 and 2021, reaching a peak value of $243.9 million in 2021, indicating a strong equity base during these years. Nevertheless, by the end of 2022, stockholders’ equity declined sharply into a deficit of $107.9 million, suggesting a deterioration in the company’s net asset position in the most recent year.
Invested capital
Invested capital remained negative for the majority of the analyzed period, starting at a deficit of $78.3 million in 2018 and worsening slightly to $106.9 million in 2019. There was a modest improvement in 2020, yet the figure remained negative. A notable positive shift occurred in 2021, with invested capital rising to a positive $91.7 million, implying effective investment and capital utilization during that year. This positive trend was reversed in 2022, with invested capital declining sharply back into negative territory at $117.4 million, reflecting a significant decrease in net capital invested in the company.

Cost of Capital

Cytokinetics Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cytokinetics Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial trajectory from 2018 through 2022 is characterized by a persistent destruction of economic value and significant volatility in the capital structure.

Economic Profit Trends
A consistent negative trend is observed in economic profit throughout the analyzed period. Although there was a momentary improvement in 2020, where losses narrowed to -19.3 million USD, the subsequent years show a rapid acceleration of value erosion. Economic losses expanded significantly to -206.8 million USD in 2021 and reached -443.1 million USD by the end of 2022, indicating a substantial increase in the gap between operating returns and the cost of capital.
Invested Capital Volatility
Invested capital displays extreme instability, fluctuating between negative and positive values. The balance remained negative from 2018 to 2020, followed by a shift to a positive 91.7 million USD in 2021. However, this trend reversed in 2022, with invested capital falling back to -117.4 million USD. Such fluctuations suggest significant shifts in the entity's financing strategy or substantial changes in the balance of assets and liabilities.
Economic Spread Ratio Analysis
The economic spread ratio, specifically recorded at -225.49% in 2021, highlights a critical deficiency in value creation. This deeply negative percentage indicates that the return on invested capital was far below the weighted average cost of capital, confirming that the entity was operating at a significant economic deficit during that fiscal year.

Economic Profit Margin

Cytokinetics Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial trajectory from 2018 to 2022 is characterized by consistent negative economic profit and extreme volatility in both revenue and margin performance. A strong correlation is observed between revenue peaks and the temporary mitigation of economic losses, although the overall trend indicates a severe deterioration in value creation by the end of the period.

Economic Profit Trends
Economic profit remained negative throughout the entire five-year period, indicating that the company did not generate returns sufficient to cover its cost of capital. A significant improvement occurred in 2020, where losses narrowed to -19,285 thousand USD. However, this was followed by a sharp downward trend, with losses expanding to -206,819 thousand USD in 2021 and reaching a period low of -443,119 thousand USD by December 31, 2022.
Adjusted Revenue Fluctuations
Adjusted revenues exhibited high instability. A substantial peak was recorded in 2020 at 142,828 thousand USD, marking a significant increase over previous years. This trend reversed sharply thereafter, with revenues falling to 70,428 thousand USD in 2021 and collapsing to 7,588 thousand USD in 2022, representing a near-total erosion of the revenue base compared to the 2020 high.
Economic Profit Margin Analysis
The economic profit margin reflects the amplified impact of widening losses coupled with shrinking revenues. The margin reached its most favorable point in 2020 at -13.50%, the closest the organization came to economic break-even. By December 31, 2022, the margin deteriorated to -5,839.74%, signaling an extreme divergence between the generated revenue and the cost of capital, which indicates a critical decline in the efficiency of value generation.